Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (311-320 of 401) with videos related to

Pageof 41
Sort By:
Revista Espanola De Cardiologia|November 26, 2011
[ESC/EAS Guidelines for the management of dyslipidaemias]Željko Reiner, Alberico L Catapano, Guy De Backer, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Circulation|June 23, 2018
Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery DiseaseRachel C Orme, William A E Parker, Mark R Thomas, et al.
Circulation. Cardiovascular Interventions|July 29, 2021
Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment-Elevation Myocardial Infarction: Insights From the COMPLETE TrialPayam Dehghani, Warren J Cantor, Jia Wang, et al.
Circulation|September 1, 2016
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)Marc P Bonaca, Shinya Goto, Deepak L Bhatt, et al.
Journal of the American Heart Association|July 29, 2025
Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI TrialRobert F Storey, John Deanfield, Stefan James, et al.
Nature Reviews. Cardiology|July 6, 2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke preventionDavide Capodanno, Roxana Mehran, Marco Valgimigli, et al.
Circulation. Cardiovascular Interventions|September 19, 2023
Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE TrialZardasht Oqab, Vijay Kunadian, David A Wood, et al.
JAMA Cardiology|September 27, 2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS TrialMariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
Pageof 41

Showing results (311-320 of 401) with videos related to

Sort By:
Pageof 41
Revista Espanola De Cardiologia|November 26, 2011
[ESC/EAS Guidelines for the management of dyslipidaemias]Željko Reiner, Alberico L Catapano, Guy De Backer, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Circulation|June 23, 2018
Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery DiseaseRachel C Orme, William A E Parker, Mark R Thomas, et al.
Circulation. Cardiovascular Interventions|July 29, 2021
Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment-Elevation Myocardial Infarction: Insights From the COMPLETE TrialPayam Dehghani, Warren J Cantor, Jia Wang, et al.
Circulation|September 1, 2016
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)Marc P Bonaca, Shinya Goto, Deepak L Bhatt, et al.
Journal of the American Heart Association|July 29, 2025
Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI TrialRobert F Storey, John Deanfield, Stefan James, et al.
Nature Reviews. Cardiology|July 6, 2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke preventionDavide Capodanno, Roxana Mehran, Marco Valgimigli, et al.
Circulation. Cardiovascular Interventions|September 19, 2023
Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE TrialZardasht Oqab, Vijay Kunadian, David A Wood, et al.
JAMA Cardiology|September 27, 2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS TrialMariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
Pageof 41